Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 4/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092893 | 0.85 | GABRA5 (0.42) | HTR7GABRA5NOS3NOS2HSD17B3 | |
| SCHEMBL15629190 | 0.84 | NOS3 (0.45) | HTR7GABRA5NOS3NOS2HSD17B3 | |
| SCHEMBL12093742 | 0.82 | GRM5 (0.48) | HTR7GABRA5NOS3NOS2HSD17B3 | |
| SCHEMBL8352809 | 0.81 | TAAR1 (0.45) | HTR7HTR1BTAAR1KDM4EKDM1A | |
| SCHEMBL12092900 | 0.81 | TSHR (0.46) | HTR7GABRA5NOS3NOS2HSD17B3 | |
| SCHEMBL9440370 | 0.81 | LMNA (0.48) | HTR7GABRA5HSD17B3CCR1CCR8 | |
| SCHEMBL10842869 | 0.81 | KMT2A (0.51) | HTR7GABRA5NOS3NOS2HSD17B3 | |
| SCHEMBL22809538 | 0.80 | SMN1; SMN2 (0.42) | TAAR1KDM4ERXRAGRIN1GRIN2B | |
| SCHEMBL5218004 | 0.79 | HSD17B3 (0.43) | HTR7GABRA5NOS3NOS2HSD17B3 | |
| SCHEMBL8234821 | 0.79 | GABRA5 (0.41) | HTR7GABRA5NOS3NOS2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020198379-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| EP-3475268-B1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2020-08-19 | — | — | EP | disclosed |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | NEUROLIXIS (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3475268-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | Neurolixis (FR) | 2019-05-01 | — | — | EP | disclosed |
| US-20180273476-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | MERCK PATENT GMBH (DE) | 2018-09-27 | — | — | US | disclosed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| WO-2017220799-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2017-12-28 | — | — | WO | disclosed |
| EP-2709985-B1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS LTD (AU) | 2017-10-04 | — | — | EP | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| EP-2524912-A1 | Amine derivatives | Bionomics Limited (AU) | 2012-11-21 | — | — | EP | disclosed |
| US-7015225-B1 | Anti-cancer agents and methods | CHEN LARRY | 2006-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | HTR7 1392/4885GABRA5 347/4885NOS3 244/4885 |
| US-20180273476-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | HTR7 1392/4885GABRA5 347/4885NOS3 244/4885 |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | HTR7 1392/4885GABRA5 347/4885NOS3 244/4885 |
| US-10562853-B2 | Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors | HTR5A, HTR1A, HTR1E | HTR7 23/4885GABRA5 133/4885NOS3 3421/4885 |
| US-20190194132-A1 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | HTR5A, HTR1A, HTR1E | HTR7 23/4885GABRA5 133/4885NOS3 3421/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | HTR7 1392/4885GABRA5 347/4885NOS3 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.